Medical News

RSS

Cardiac Science and Gust Bardy launch innovation center to develop cost-effective medical products and services

Cardiac Science Corporation, a global leader in automated external defibrillator (AED) and diagnostic cardiac monitoring devices, has joined with Gust Bardy, MD to create an innovation center focused on the development and commercialization of simple, cost-effective medical products and services that positively impact public health.

11 Jan 2010

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that it has expanded its existing license agreement with the University of Pennsylvania, adding exclusive worldwide licenses for technology and intellectual property for novel DNA vaccines against pandemic influenza, Chikungunya, and foot-and-mouth disease.

11 Jan 2010

RMMC selects Allscripts' EHR and Practice Management solutions

Allscripts announced today that Renaissance Medical Management Company (RMMC) has selected the company's Electronic Health Record (EHR) and Practice Management solution to automate and connect clinical and administrative processes for a minimum of 51 family practice and internal medicine physicians.

11 Jan 2010

Illumina launches HumanOmniExpress BeadChip for GWAS

Illumina, Inc. today announced the HumanOmniExpress BeadChip (OmniExpress), the newest addition to the Omni family of microarrays for genome-wide association studies (GWAS).

From Illumina, Inc. 11 Jan 2010

ImpactRx executes $1.2 million Series E round of financing

ImpactRx® announced today that the company has executed a Series E round of financing in the amount of $1.2 million, of which the first tranche of $678,040 was closed on December 23, 2009. ImpactRx is the pioneering force in measuring the impact of pharmaceutical promotion on the prescribing behavior of the nation's highest value physicians.

11 Jan 2010

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced it has received the final milestone payment of $2.5 million from an affiliate of Paul Capital Healthcare.

11 Jan 2010

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

SRI International Dedicates New Tampa Bay Research Facility SRI International, one of the world's leading independent research and technology development organizations, officially opened its new 40,000-square-foot research facility located at the Port of St. Petersburg.

11 Jan 2010

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

The INSTITUT CURIE and IPSOGEN (FR0010626028 - ALIPS) announce the signing of a scientific collaboration agreement in the breast cancer domain. Within the framework of this project, the current scientific knowledge on Ipsogen's MapQuant Dx Grade Genomic, HER2 and HR tests will be increased thanks to new data established from a large population of patients treated at the Institut Curie.

11 Jan 2010

New technique may help researchers to test amyloid hypothesis in AD development

Current Alzheimer's disease (AD) research indicates that accumulation of amyloid-beta (Aβ) protein plaques in the brain is central to the development of AD.

11 Jan 2010

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Mirna Therapeutics announced today that the Company received a $5 million award from the State of Texas through the Texas Emerging Technology Fund (“ETF”). The ETF was created with the goal of growing new and existing businesses to accelerate the introduction of new products and services in the marketplace. This is the largest award of this type that has ever been granted.

11 Jan 2010

Gerresheimer Group sets up new medical plastic systems production facility in Brazil

The Gerresheimer Group has set up a new facility for medical plastic systems in Indaiatuba (Brazil). The plant is to commence operations early in 2010. On the basis of a long-term cooperation agreement with Novo Nordisk, components will be produced with state-of-the-art technology for insulin pen systems for diabetics.

11 Jan 2010

Biotage finalizes transfer of its manufacturing business from Charlottesville, Virginia

Biotage announced on 22 January 2009 that the company had decided to move the manufacturing of its products from its factory in Charlottesville, Virginia, to contract manufacturers and Biotage’s manufacturing plant in Cardiff, Wales. The transfer of this business has now successfully been finalized.

11 Jan 2010

Meda receives exclusive rights to distribute AML drug in Europe and Asia

Meda has in-licensed exclusive rights to Ceplene (histamine dihydrochloride) from EpiCept Corporation, a US-based biopharmaceutical company.

11 Jan 2010

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

KaloBios Pharmaceuticals, Inc. today announced an agreement with Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, for the development and commercialization of KB001, an investigational new biologic for the treatment or prevention of Pseudomonas aeruginosa (Pa) infections. Sanofi Pasteur will be responsible for the development and commercialization of KB001 and initially focus on hospital indications, including the prevention of Pa pneumonias in mechanically ventilated patients.

11 Jan 2010

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

EpiCept Corporation announced today that it has entered into an exclusive commercialization agreement for Ceplene® (histamine dihydrochloride) with Meda AB, a leading international specialty pharmaceutical company based in Stockholm. Ceplene is EpiCept’s novel therapy approved in the European Union with orphan drug status for the remission maintenance and prevention of relapse of patients with acute myeloid leukemia (AML) in first remission.

11 Jan 2010

Sanofi-aventis commences tender offer for Chattem through River Acquisition

Sanofi-aventis announced today the commencement of a tender offer through its wholly-owned subsidiary, River Acquisition Corp., for all outstanding shares of common stock of Chattem, Inc. for $93.50 per share, net to the seller in cash, without interest and less any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated January 11, 2010, and in connection with the previously announced Agreement and Plan of Merger, dated December 20, 2009, among sanofi-aventis, River Acquisition Corp. and Chattem, Inc.

11 Jan 2010

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

“More and more physicians are realizing that prescriptions that leave the office are like money walking out of the door,” said Fred Ganjian, Vice President of Sales and Marketing for Bryant Ranch Prepack, a leading supplier of prepackaged physician-dispensed prescription programs. “In this day of continuing pressure on physicians to cover their costs, physician-dispensed prescriptions have become increasingly important to a physician’s bottom line,” he added.

11 Jan 2010

WuXi AppTec enters into partnership with QIAGEN

WuXi AppTec Inc. today announced that it has entered into a partnership with QIAGEN to provide an integrated single solution for molecular biomarker development, validation and personalized healthcare targets to their respective client bases.

From QIAGEN Manchester Limited 11 Jan 2010

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Scientists at deCODE genetics today report the discovery of seven novel and common single-letter variations in the sequence of the human genome (SNPs) that are involved in modulating the electrical impulses that govern the working of the heart.

11 Jan 2010

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Vertex Pharmaceuticals Incorporated today provided an update on key 2010 business priorities in conjunction with the 28th Annual J.P. Morgan Healthcare Conference in San Francisco. The company also discussed recent progress in its lead development programs in hepatitis C virus (HCV) infection and cystic fibrosis (CF) and outlined proof-of-concept clinical trials planned in other serious diseases for 2010.

11 Jan 2010

Medical News

Cardiac Science and Gust Bardy launch innovation center to develop cost-effective medical products and services

Inovio Biomedical expands existing license agreement with the University of Pennsylvania

RMMC selects Allscripts' EHR and Practice Management solutions

Illumina launches HumanOmniExpress BeadChip for GWAS

ImpactRx executes $1.2 million Series E round of financing

A.P. Pharma receives final milestone payment of $2.5M from Paul Capital Healthcare

Tampa Bay Partnership releases new briefs on the economic and business growth in the Tampa Bay Region

Institut Curie, Ipsogen sign scientific collaboration agreement in breast cancer domain

New technique may help researchers to test amyloid hypothesis in AD development

Mirna Therapeutics receives ETF award to develop miRNA therapeutics for multiple cancers

Gerresheimer Group sets up new medical plastic systems production facility in Brazil

Biotage finalizes transfer of its manufacturing business from Charlottesville, Virginia

Meda receives exclusive rights to distribute AML drug in Europe and Asia

KaloBios Pharmaceuticals, Sanofi Pasteur partner in development of KB001 biologic for Pa infections

EpiCept, Meda enter into exclusive commercialization agreement for Ceplene

Sanofi-aventis commences tender offer for Chattem through River Acquisition

Bryant Ranch Prepack tracks medications from its manufacture to the patient with E Pedigree

WuXi AppTec enters into partnership with QIAGEN

Variations in SNPs involved in modulating electrical impulse that govern working of heart discovered

Vertex Pharmaceuticals plans proof-of-concept clinical trials in RA and epilepsy

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News